share_log

ODAIA to Showcase the Impact of AI in Pharma at Upcoming Industry Events

ODAIA to Showcase the Impact of AI in Pharma at Upcoming Industry Events

ODAIA將在即將舉行的行業活動中展示人工智能對製藥的影響
PR Newswire ·  04/23 07:05

TORONTO, April 23, 2024 /PRNewswire/ -- Pharma experts and AI innovators from ODAIA will be the featured presenters at top industry events this spring. Speakers will share how pharma companies are advancing their commercial strategies using Customer Science, a transformative discipline that integrates AI with data science and behavioral science for a deeper understanding of healthcare professionals (HCPs) and what motivates their patient decisions.

多倫多,2024 年 4 月 23 日 /PRNewswire/ — 來自多倫多的製藥專家和人工智能創新者 奧達亞 將成爲今年春季頂級行業活動的特邀主持人。演講者將分享製藥公司如何使用以下方法推進其商業戰略 客戶科學,這是一門變革性學科,將人工智能與數據科學和行爲科學相結合,旨在加深對醫療保健專業人員(HCP)及其患者決策動機的理解。

Veeva Commercial Summit, Boston, May 8, at 12:30 p.m. EST

Veeva 商業峯會,波士頓,美國東部標準時間5月8日下午 12:30

Philip Poulidis, CEO, will demonstrate the use of AI to find, select, and engage the right HCPs. It typically takes months for marketing to complete customer segmentation and targeting, which is refreshed once or twice a year. When there's a marketplace change, an entirely new data analysis must be done, taking more months before sales gets updated plans of action to start engaging HCPs.

首席執行官菲利普·普利迪斯,將演示如何使用人工智能來查找、選擇和聘用合適的 HCP。營銷部門通常需要幾個月的時間才能完成客戶細分和定位,每年更新一次或兩次。當市場發生變化時,必須進行全新的數據分析,再過幾個月,銷售人員才能更新行動計劃,開始與HCP合作。

Poulidis will show ODAIA MAPTUAL completing this process in minutes, not months. Marketing can set new brand objectives, use advanced AI capabilities to automate data analysis, and deliver personalized GenAI-powered insights in Veeva CRM MyInsights. Sales reps can prioritize which HCPs to contact, how best to engage them, and get treatments to patients months faster.

Poulidis 將露面 奧達亞馬耳他人 在幾分鐘而不是幾個月內完成此過程。營銷可以設定新的品牌目標,使用先進的人工智能功能來自動進行數據分析,並在以下方面提供基於Genai的個性化見解 Veeva CRM 我的見解。銷售代表可以優先聯繫哪些 HCP,如何最好地與他們互動,並縮短數月爲患者提供治療。

PMSA 2024 Annual Conference, Denver, Colo., May 8, at 11:10 a.m. EST

PMSA 2024 年年會,科羅拉多州丹佛,美國東部標準時間5月8日上午11點10分

Matthieu Buot de l'Epine, lead machine learning engineer, and Pouyan Jahangiri, director of data science and machine learning, will discuss improving prediction accuracy in prescription modeling using hierarchical machine learning techniques and time series data. Creating accurate and consistent forecasts at the individual HCP, territory, state, and national levels is critical in the pharma industry because of the limited shelf life for medicines and significant impact of prediction errors to resource allocations, financial planning, and regulatory compliance.

Matthieu Buot de l'Epine,首席機器學習工程師,以及 數據科學和機器學習總監 Pouyan Jahangiri,將討論使用分層機器學習技術和時間序列數據提高處方建模的預測準確性。由於藥品的保質期有限,而且預測錯誤會對資源分配、財務規劃和監管合規性產生重大影響,因此在個別HCP、地區、州和國家層面創建準確和一致的預測對於製藥行業至關重要。

Buot de l'Epine and Jahangiri will discuss how a hierarchical model enables simultaneous predictions and outputs at every level and integrates insights for better consistency and accuracy in forecasting, supporting pharma companies in planning and executing their commercial strategies more efficiently and effectively.

Buot de l'Epine和Jahangiri將討論分層模型如何實現各個層面的同步預測和輸出,如何整合見解,以提高預測的一致性和準確性,支持製藥公司更高效地規劃和執行其商業戰略。

Reimagine Pharma Marketing, Long Branch, N.J., May 21, at 1:45 p.m. EST

重新構想藥品營銷,新澤西州朗布蘭奇,美國東部標準時間5月21日下午 1:45

Eric Trépanier, chief strategy and customer officer, will be joined on stage with a top 10 pharma customer to discuss the use of AI to provide never-before-seen insights into HCPs and dramatically improve marketing and sales rep decision-making. Traditional approaches like next best action and segmentation and targeting fall short in delivering meaningful customer experiences.

埃裏克·特雷帕尼爾,首席戰略和客戶官,將與排名前十的製藥客戶一起登臺,討論如何使用人工智能爲HCP提供前所未有的見解,並顯著改善營銷和銷售代表的決策。次佳行動、細分和定位等傳統方法不足以提供有意義的客戶體驗。

Speakers will share how commercial pharma innovators are embracing Customer Science to better understand HCPs and drive engagement. Commercial organizations can break the limitations of rules-based systems and historical data analysis to deliver valued HCP experiences using real-time, relevant insights.

演講者將分享商業製藥創新者如何利用客戶科學來更好地了解HCP並提高參與度。商業組織可以打破基於規則的系統和歷史數據分析的侷限性,使用實時、相關的見解提供有價值的 HCP 體驗。

Snowflake Data Cloud Summit 24, San Francisco Calif., June 5, at 3:30 p.m. PST

Snowflake 數據雲峯會 24,加利福尼亞州舊金山,太平洋標準時間6月5日下午 3:30

Phillip Poulidis, CEO, and Zak Beharie, CTO, will discuss the successful deployment of machine learning applications for commercial use cases in pharma. The process for transferring data includes cumbersome secure file transfer protocols (SFTPs), slow computing power, and complex data agreements.

首席執行官菲利普·普利迪斯和 首席技術官 Zak Beharie,將討論在製藥業商業用例中成功部署機器學習應用程序。傳輸數據的過程包括繁瑣的安全文件傳輸協議 (SFTP)、緩慢的計算能力和複雜的數據協議。

Poulidis and Beharie will share how to overcome data transfer limitations using the Snowflake Native App Framework, ODAIA machine learning, and pharma customers' proprietary data to achieve better ROI. Customers retain total data control, streamline their commercial processes, and seamlessly deliver predictive insights to their commercial organization.

Poulidis 和 Beharie 將分享如何使用以下方法克服數據傳輸限制 Snowflake 原生應用程序框架、ODAIA 機器學習和製藥客戶的專有數據,以實現更高的投資回報率。客戶保留全面的數據控制權,簡化商業流程,並無縫地向其商業組織提供預測性見解。

To learn more about ODAIA, schedule a meeting with our team at Veeva Summit, PMSA, Reimagine, and Snowflake Data Cloud Summit. Learn more about all our upcoming events here.

要了解有關 ODAIA 的更多信息,請安排與我們的團隊會面 Veeva 峯會PMSA重新構想,以及 Snowflake 數據雲峯會。了解有關我們所有內容的更多信息 即將舉行的活動在這裏

About ODAIA
ODAIA is the leading AI company helping life sciences companies innovate their commercial strategies using Customer Science. The company's cloud solution, MAPTUAL, integrates data science, behavioral science, and AI to gain a deep understanding of healthcare professionals (HCPs) and their patient decisions across the entire customer journey. To learn more about ODAIA, visit our website or follow us on LinkedIn.

關於 ODAIA
ODAIA是領先的人工智能公司,幫助生命科學公司利用客戶科學創新其商業策略。該公司的雲解決方案MAPTUAL集成了數據科學、行爲科學和人工智能,以深入了解醫療保健專業人員(HCP)及其在整個客戶旅程中的患者決策。要了解有關 ODAIA 的更多信息,請訪問 我們的網站 或者關注我們 領英

SOURCE ODAIA

來源 ODAIA

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論